449 related articles for article (PubMed ID: 17700265)
1. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
[TBL] [Abstract][Full Text] [Related]
2. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
Koutroubakis IE; Oustamanolakis P; Malliaraki N; Karmiris K; Chalkiadakis I; Ganotakis E; Karkavitsas N; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
[TBL] [Abstract][Full Text] [Related]
3. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Valentini L; Wirth EK; Schweizer U; Hengstermann S; Schaper L; Koernicke T; Dietz E; Norman K; Buning C; Winklhofer-Roob BM; Lochs H; Ockenga J
Nutrition; 2009 Feb; 25(2):172-81. PubMed ID: 18849144
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin, resistin and leptin response to dietary intervention in diabetic nephropathy.
Kozłowska L; Rydzewski A; Fiderkiewicz B; Wasińska-Krawczyk A; Grzechnik A; Rosołowska-Huszcz D
J Ren Nutr; 2010 Jul; 20(4):255-62. PubMed ID: 20537918
[TBL] [Abstract][Full Text] [Related]
5. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men.
Oh KW; Lee WY; Rhee EJ; Baek KH; Yoon KH; Kang MI; Yun EJ; Park CY; Ihm SH; Choi MG; Yoo HJ; Park SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):131-8. PubMed ID: 16060905
[TBL] [Abstract][Full Text] [Related]
6. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
[TBL] [Abstract][Full Text] [Related]
7. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
[TBL] [Abstract][Full Text] [Related]
8. Adipocytokines and breast cancer risk.
Hou WK; Xu YX; Yu T; Zhang L; Zhang WW; Fu CL; Sun Y; Wu Q; Chen L
Chin Med J (Engl); 2007 Sep; 120(18):1592-6. PubMed ID: 17908478
[TBL] [Abstract][Full Text] [Related]
9. Leptin, adiponectin, resistin, and ghrelin--implications for inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Kouroumalis EA
Mol Nutr Food Res; 2008 Aug; 52(8):855-66. PubMed ID: 18383234
[TBL] [Abstract][Full Text] [Related]
10. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men.
Peng XD; Xie H; Zhao Q; Wu XP; Sun ZQ; Liao EY
Clin Chim Acta; 2008 Jan; 387(1-2):31-5. PubMed ID: 17884030
[TBL] [Abstract][Full Text] [Related]
11. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality.
Taskapan MC; Taskapan H; Sahin I; Keskin L; Atmaca H; Ozyalin F
Ren Fail; 2007; 29(2):147-54. PubMed ID: 17365928
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease.
Díez JJ; Iglesias P; Fernández-Reyes MJ; Aguilera A; Bajo MA; Alvarez-Fidalgo P; Codoceo R; Selgas R
Clin Endocrinol (Oxf); 2005 Feb; 62(2):242-9. PubMed ID: 15670203
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men.
Gouni-Berthold I; Berthold HK; Chamberland JP; Krone W; Mantzoros CS
Clin Endocrinol (Oxf); 2008 Apr; 68(4):536-41. PubMed ID: 17973945
[TBL] [Abstract][Full Text] [Related]
15. Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis.
Toussirot E; Streit G; Nguyen NU; Dumoulin G; Le Huédé G; Saas P; Wendling D
Metabolism; 2007 Oct; 56(10):1383-9. PubMed ID: 17884449
[TBL] [Abstract][Full Text] [Related]
16. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.
Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
Fundam Clin Pharmacol; 2009 Oct; 23(5):595-600. PubMed ID: 19563510
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
Tasaka S; Hasegawa N; Nishimura T; Yamasawa W; Kamata H; Shinoda H; Kimizuka Y; Fujiwara H; Hirose H; Ishizaka A
Respiration; 2010; 79(5):383-7. PubMed ID: 19641295
[TBL] [Abstract][Full Text] [Related]
18. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study.
Dalamaga M; Karmaniolas K; Panagiotou A; Hsi A; Chamberland J; Dimas C; Lekka A; Mantzoros CS
Cancer Causes Control; 2009 Mar; 20(2):193-9. PubMed ID: 18814045
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis.
Tiftikci A; Atug O; Yilmaz Y; Eren F; Ozdemir FT; Yapali S; Ozdogan O; Celikel CA; Imeryuz N; Tozun N
Arch Med Res; 2009 May; 40(4):294-8. PubMed ID: 19608019
[TBL] [Abstract][Full Text] [Related]
20. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
